AMD

Optigo Biotherapeutics presents promising preclinical data at ARVO.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials for EYP-1901 against aflibercept for the treatment of wet macular degeneration.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Insights from a genome-wide association study identify novel genetic loci

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The first session of the 2025 COPHy meeting was titled "Big controversies in retina and beyond in 2025.”